

Cryptosporidium muris Infection in an HIV-Infected Adult, Kenya

Wangeci Gatei,*†Richard W. Ashford,* Nicholas J. Beeching,* S. Kang'ethe Kamwati,‡ Julie Greensill,† and C. Anthony Hart†

We describe a case of *Cryptosporidium muris* infection in an HIV-infected adult with diarrhea in Kenya. Sequence analysis of an 840-bp region of the 18S rRNA gene locus demonstrated the isolate had 100% nucleotide identity with *C. muris* recovered from a rock hyrax, 98.8% with a *C. muris* "calf" isolate, 95.5% with *C. serpentis*, but only 87.8% with *C. parvum* "human" type.

Tyzer identified the first *Cryptosporidium* species, *C. muris*, in the gastric glands of mice (1). Thereafter, he identified *C. parvum*, which infects the small intestines of many mammals, and described the complete coccidian life cycle. Over the next 70 years, more than 23 different species of the genus were described on the basis of their morphology and natural hosts. However, when animals were experimentally infected, many of the described *Cryptosporidium* species were found to be identical. In the 1970s the classification was revised, and today only six to eight species are recognized as valid, with most human, zoonotic, and mammalian infections being attributed to the different *C. parvum* genotypes (2,3). *C. muris*, which is naturally a murine parasite, appears to have a more limited host range than *C. parvum*. Experimental transmission studies of *C. muris* have shown that the isolate from laboratory mice can infect other animals, including dogs, guinea pigs, rabbits, lambs, and gerbils, although it did not produce patent infections (4). The parasite has also been isolated from a rock hyrax (*Procapra* sp.) from a zoo and a Bactrian camel with chronic cryptosporidiosis (3,5). For many years, the parasite was thought to infect cattle; however, recent studies have shown that the *C. muris* that infects cattle is genetically distinct, and a new species name, *C. andersoni*, has been suggested (6).

Conventional diagnostic methods for *Cryptosporidium* do not differentiate the various species and genotypes, and most infections are diagnosed as *C. parvum*. *C. parvum* "human" and "bovine" genotypes remain the main causes of human cryptosporidiosis, but lately identification of infections with other genotypes and also *Cryptosporidium* species other than

C. parvum has increased in both immunosuppressed and immunocompetent persons (7-10). Possible asymptomatic human infection with *C. muris* was reported in two healthy girls in Indonesia (11). Morphologic studies on the oocysts showed they were most likely to be *C. muris*, although there was no genotypic or experimental animal confirmation. Phylogenetic analysis has enabled more conclusive assignment to species and genotypes infecting humans and other animals (12,13). We report a case of *C. muris* infection, confirmed by morphology and genotyping, in an adult HIV-infected man from Kenya, hospitalized with diarrhea.

The Study

Fecal samples were collected from diarrheal patients from a hospital in Nairobi, Kenya, as part of a larger study. The patient described was an HIV-infected man who had clinical tuberculosis and diarrhea. *Isoospora belli* was also detected in a fecal sample from the patient.

The fecal samples were preserved in both sodium acetate formalin and 2.5% potassium dichromate and kept at 4°C. They were stained with Kinyoun's carbol fuchsin modified acid-fast stain and examined by oil immersion microscopy. An aliquot of 400 µL of the sample suspension in 2.5% potassium dichromate was processed for genotypic analysis. Potassium dichromate was washed 5 times with cold, distilled water until the yellow color cleared. Oocysts were ruptured by freeze-thaw, and DNA was extracted by using a QIAamp DNA Mini Kit (Qiagen, West Sussex, UK) for stool DNA purification as per protocol.

A section of the SSU (18S) rRNA gene was amplified by nested polymerase chain reaction (PCR) as described (14), using the forward primers 5'-TTCTAGAGCTAATACATGCG-3' and the reverse primer 5'-CCCTAATCCTTCGAAACAGGA-3' for primary PCR. Secondary PCR used primers 5'-GGAAGGGTTGATTTATTAGATAAAG-3' and reverse primer 5'-AAGGAGTAAGGAACAACCTCCA-3', employing the Techne (FTGENE2D Techne, Cambridge Ltd., UK) thermal cycler. Restriction fragment analysis of the secondary PCR product was done by digesting 15 µL of product in a 40-mL total reaction volume consisting of 15 U of *Ssp1* and 3 µL of restriction buffer (Boehringer Mannheim Biochemicals, Indianapolis, IN) for species identification and *Asn1* (Boehringer Mannheim) for genotyping in the same concentration at 37°C for 1 hour. Digestion products were separated on 2% agarose gel and visualized by ethidium bromide staining. The internal (secondary) fragment was purified by using the Prep-A-Gene DNA purification kit and cloned into PGEM-T Easy plasmid vector (Promega Corporation, Madison, WI) as described by the manufacturer. The cloned product was sequenced and aligned with previously published sequences of the 18S rRNA gene of *Cryptosporidium* species by using the CLUSTALX (EMBL, Heidelberg, Germany) program and manual adjustments. Multiple alignment was done with the Phylogeny Inference Package (PHYLIP version 3.5c, J. Felsenstein and the University of Washington, Seattle, WA). Sequences were analyzed by using

*Liverpool School of Tropical Medicine, Liverpool, United Kingdom; †University of Liverpool, Liverpool, United Kingdom; and ‡Kenya Medical Research Institute, Nairobi, Kenya

DNADIST followed by neighbor joining (NEIGHBOR, PHYLIP package). One hundred replica samplings were analyzed for percentage bootstrap values. Accession numbers for *Cryptosporidium* 18S rRNA genes used were AF093498, AF093497, AF093496, AF108866 and AF093489, AF093499, AF112569 AF115377.

Results

Microscopic examination of the acid-fast stained fecal smear revealed ovoid oocysts that were an average size of 7.5-9.8 x 5.5-7.0 μm (Figure 1). Cysts of *I. belli* were also identified in the stained smear.

Restriction endonuclease digestion with *Ssp1* of the secondary PCR 18S rRNA product yielded two fragments of 385 bp and 448 bp in size, while *Asn1* digestion yielded two visible bands that were 102 bp and 731 bp. The results match restriction fragment patterns observed following similar digestions of *C. muris* amplicons from rock hyrax and Bactrian camel isolates (14).

The resulting sequence 18S rRNA gene fragment of the *C. muris* human isolate was deposited in the EMBL Nucleotide Sequence Database (Accession no. AJ307669). Sequence analysis with ClustalX showed this human *C. muris* isolate had a 100% nucleotide identity to that of a *C. muris* isolate from a rock hyrax and a Bactrian camel (EMBL Accession no. AF093498, AF093497), 98.8% identity to a *C. muris* "calf" isolate (AF093496), 96.5% with *C. serpentis* (AF108866), and only 87.8% identity to *C. parvum* human type (AF093489). *C. muris* calf isolate (AF093496) has since been shown to be a different species from *C. muris* ("mouse" type, Accession no. AF093498) and has been given a new name, *C. andersoni*. The phylogenetic tree showed topology similar to that already published for *Cryptosporidium*, with *C. parvum* clustering in one clade, and our patient's sample and published sequences of *C. muris* (rock hyrax isolate), *C. andersoni* (calf isolate), and *C. serpentis* clustered in another group (Figure 2).




Figure 1. *Cryptosporidium muris* oocysts (under oil X 1,000), stained by Kinyoun's acid-fast staining.

Conclusions

Our study used genotypic analysis to confirm microscopic detection of *Cryptosporidium* oocysts in fecal samples and indicated that *C. muris* can indeed infect humans. Although immunosuppression has been observed to produce an increased susceptibility to cryptosporidiosis, the range of *Cryptosporidia* that can cause human cryptosporidiosis is still being elucidated (8,13,15). Lately, novel genotypes and non-*C. parvum* species such as *C. meleagridis*, *C. felis*, and *C. parvum* "dog" type have been identified not only in HIV-infected persons but also in HIV-uninfected patients (7,9,10). Genotypic analysis of *Cryptosporidium* organisms in fecal samples in the United Kingdom showed the occurrence of *C. meleagridis*, *C. felis*, and *C. parvum* "dog" type in immunocompetent and immunosuppressed persons (10,16). In another study in Peru, *C. felis*, *C. parvum* "dog" type, and *C. meleagridis* were identified in children not infected with HIV. In that study, *C. meleagridis* was as common as *C. parvum* "bovine" type; it appeared to be a stable part of the enteric pathogen mix causing cryptosporidiosis, perhaps only being identified with current definitive molecular methods (9).




Figure 2. Comparison of 18S rRNA gene sequences of *Cryptosporidium* species. K33-*C. muris* from human patient (current paper Accession no. AJ307669); *C. m (muris)* "rock hyrax" (Accession no. AF093498); *C. m. (muris)* "calf" isolate (AF093496), now renamed *C. andersoni*; *C. serpentis* (AF093499); *C. p (parvum)* "dog" (AF112576); *C. p. "rhesus monkey"* (AF112569); *C. p. "human"* (AF093489); and *C. p. "pig"* (AF115377). Numbers refer to the percentage of repeated analyses that gave the same tree topology (bootstrap values).

C. muris infects the gastric glands of immunocompetent or immunocompromised (nude and SCID) mice (17); however, since our patient was co-infected with *I. belli*, the role of *C. muris* in our patient's gastroenteritis and its possible site of infection in this patient are unclear.

A report of possible asymptomatic *C. muris* infection in healthy persons (11) and our finding of it in an immunosuppressed patient suggest that this may be yet another *Cryptosporidium* species with a zoonotic potential. The range of animal reservoir hosts in which *C. muris* has been identified or experimentally transmitted adds to the importance of *Cryptosporidium* species as a public health concern (3,4,15). The current genotypic analyses are making it possible to make more conclusive diagnoses and to speculate on possible sources of infection (14-16). These techniques will need to be applied more widely to identify and characterize isolates of *Cryptosporidium* for more definitive epidemiologic mapping.

Acknowledgments

We thank Winifred Dove, F.B. Kiliku, and Njeri Wamae for their assistance.

The study is part of a doctoral research grant to Wangeci Gatei from the Association of Commonwealth Universities at the Liverpool School of Tropical Medicine, United Kingdom.

Wangeci Gatei is a Commonwealth Universities Scholar, working toward a doctorate in parasitology in the Tropical and Medical Schools, University of Liverpool. She qualified in veterinary medicine in 1987 and since then has worked at the Kenya Medical Research Institute in Nairobi as a veterinary parasitologist.

References

1. Tyzzer EE. A sporozoan found in the peptic glands of the common mouse. *Proc Soc Exp Biol Med* 1907; 5:12-13.
2. Levine ND. Taxonomy and review of the coccidian genus *Cryptosporidium* (Protozoa, Apicomplexa) *J Protozool* 1984;31:94-8.
3. Tzipori S, Griffiths JK. Natural history and biology of *Cryptosporidium parvum*. In: Baker JR, Muller R, Rollison D, Tzipori S. *Advances in parasitology: Opportunistic protozoa in humans*. Vol. 40. London: Academic Press; 1998. p. 5-35.
4. Aydin Y, Ozkul IA. Infectivity of *Cryptosporidium muris* directly isolated from the murine stomach for various laboratory animals. *Vet Parasitol* 1996; 66:257-62.
5. Fayer R, Phillips L, Anderson BC, Bus M. Chronic cryptosporidiosis in a bactrian camel (*Camelus bactrianus*). *J Zoo Wildl Med* 1991; 22:228-32.
6. Lindsay DS, Upton SJ, Owens DS, Morgan UM, Mead JR, Blagburn BL. *Cryptosporidium andersoni* n. sp. (Apicomplexa: Cryptosporiidae) from cattle, *Bos taurus*. *J Eukaryot Microbiol* 2000;47:91-5.
7. Morgan U, Weber R, Xiao L, Sulaiman I, Thompson RC, Ndiritu W, et al. Molecular characterization of *Cryptosporidium* isolates obtained from human immunodeficiency virus-infected individuals living in Switzerland, Kenya, and the United States. *J Clin Microbiol* 2000;38:1180-3.
8. Pieniazek NJ, Bornay-Llinares FJ, Slemenda SB, da Silva AJ, Moura IN, Arrowood MJ, et al. New *Cryptosporidium* genotypes in HIV-infected persons. *Emerg Infect Dis* 1999; 5: 444-9.
9. Xiao L, Bern C, Limor J, Sulaiman I, Roberts J, Checkley W, et al. Identification of 5 types of *Cryptosporidium* parasites in children in Lima, Peru. *J Infect Dis* 2001; 183:492-7.
10. Pedraza-Diaz S, Amar C, Iversen AM, Stanley PJ, McLauchlin J. Unusual *Cryptosporidium* species recovered from human faeces: first description of *Cryptosporidium felis* and *Cryptosporidium* 'dog type' from patients in England. *J Med Microbiol* 2001; 50:293-6.
11. Katsumata T, Hosea D, Ranuh IG, Uga S, Yanagi T, Kohno S. Short report: possible *Cryptosporidium muris* infection in humans. *Am J Trop Med Hyg* 2000; 62:70-2.
12. Xiao L, Escalante L, Yang C, Sulaiman I, Escalante AA, Montali RJ, et al. Phylogenetic analysis of *Cryptosporidium* parasites based on the small-subunit rRNA gene locus. *Appl Environ Microbiol* 1999; 65:1578-83.
13. Morgan U, Xiao L, Sulaiman I, Weber R, Lal AA, Thompson RC, et al. Which genotypes/species of *Cryptosporidium* are humans susceptible to? *J Eukaryot Microbiol* 1999; 46:42S-43S.
14. Xiao L, Morgan UM, Limor J, Escalante A, Arrowood M, Shulaw W, et al. Genetic diversity within *Cryptosporidium parvum* and related *Cryptosporidium* species. *Appl Environ Microbiol* 1999; 65:3386-91.
15. Xiao L, Morgan UM, Fayer R, Thompson RC, Lal AA. *Cryptosporidium* systematics and implications for public health. *Parasitol Today* 2000;16:287-92. (Review).
16. McLauchlin J, Amar C, Pedraza-Diaz S, Nichols GL. Molecular epidemiological analysis of *Cryptosporidium* spp. in the United Kingdom: results of genotyping *Cryptosporidium* spp. in 1,705 fecal samples from humans and 105 fecal samples from livestock animals. *J Clin Microbiol* 2000; 38:3984-90.
17. McDonald V, Deer R, Uni S, Iseki M, Bancroft GJ. Immune responses to *Cryptosporidium muris* and *Cryptosporidium parvum* in adult immunocompetent or immunocompromised (nude and SCID) mice. *Infect Immun* 1992; 60:3325-31.

*Address for correspondence: CA Hart, Department of Medical Microbiology and Genito-Urinary Medicine, University of Liverpool, Duncan Building, Daulby Street, Liverpool, L69 3GA, UK; fax: 44-151-706-5805; e-mail: cahmm@liverpool.ac.uk.